Integrated Biopharma (Integrated Biopharma) Change In Inventory : $-1.23 Mil (TTM As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Integrated Biopharma Change In Inventory?

Integrated Biopharma's change in inventory for the quarter that ended in Mar. 2024 was $-0.91 Mil. It means Integrated Biopharma's inventory increased by $0.91 Mil from Dec. 2023 to Mar. 2024 .

Integrated Biopharma's change in inventory for the fiscal year that ended in Jun. 2023 was $0.79 Mil. It means Integrated Biopharma's inventory declined by $0.79 Mil from Jun. 2022 to Jun. 2023 .

Integrated Biopharma's Total Inventories for the quarter that ended in Mar. 2024 was $11.17 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Integrated Biopharma's Days Inventory for the quarter that ended in Mar. 2024 was 89.41.

Inventory Turnover measures how fast the company turns over its inventory within a year. Integrated Biopharma's Inventory Turnover for the quarter that ended in Mar. 2024 was 1.02.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Integrated Biopharma's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.89.

Integrated Biopharma Change In Inventory Historical Data

The historical data trend for Integrated Biopharma's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integrated Biopharma Change In Inventory Chart

Integrated Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Inventory

Get a 7-Day Free Trial

-1.08

-1.28

-1.59

0.64

0.79

Integrated Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Inventory	Get a 7-Day Free Trial															0.33	-0.32	-0.25	0.25	-0.91

Integrated Biopharma Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.23 Mil.

Integrated Biopharma (OTCPK:INBP) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Integrated Biopharma's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	11.659	/	11.899	*	365 / 4
	=	89.41

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Integrated Biopharma's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	11.899	/	11.659
	=	1.02

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Integrated Biopharma's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	11.659	/	13.147
	=	0.89

Integrated Biopharma Change In Inventory Related Terms

Thank you for viewing the detailed overview of Integrated Biopharma's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Integrated Biopharma (Integrated Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Integrated Biopharma Inc (OTCPK:INBP) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

225 Long Avenue, Building 15, Hillside, NJ, USA, 07205

Website

http://www.ibiopharma.com

Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments; Contract Manufacturing and Other Nutraceutical Businesses. It serves the needs of the nutraceutical industry by directly doing business as Chem International Inc. and through its operating subsidiaries; Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc. and MDC Warehousing and Distribution, Inc. The company generates maximum revenue from the Contract Manufacturing segment. The business operates and generates the majority of revenue from the United States.

Executives

Damon Desantis	director	2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
William H. Milmoe	director, 10 percent owner	3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Joseph Laplaca	director	72 EUGENE DRIVE, MONTVILLE NJ 07045
E Gerald Kay	director, 10 percent owner, officer: Chairman and CEO	C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Bradley J Hoecker	director	STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Jeffrey R Leach	director, officer: President and CEO
Glenn Chang	director	C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Vidadi Yusibov	director	C/O IBIOPHARMA, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Cd Financial, Llc	10 percent owner	3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Kay Riva	director, officer: Vice President	C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Christina Kay	director, officer: Vive President	C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Robert Canarick	director	C/O INTEGRATED BIOPHARMA, INC., 201 ROUTE 22, HILLSIDE NJ 07205
Robert Kay	director	C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Dina Masi	officer: Chief Financial Officer	14 LEXINGTON WAY, LONG VALLEY NJ 07853
Carl Desantis	director, 10 percent owner	C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431